Inukai T, Inukai Y, Matsutomo R, Okumura K, Takanashi K, Takebayashi K, Tayama K, Aso Y, Takemura Y
Department of Internal Medicine, Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya-shi, Japan.
J Int Med Res. 2004 Mar-Apr;32(2):206-13. doi: 10.1177/147323000403200214.
This uncontrolled study investigated the effects of using the alpha 1-blocker doxazosin (2 mg or 4 mg daily for 3 months) to treat 21 hypertensive patients with type 2 diabetes, including eight obese individuals (body mass index [BMI] > or = 25.0 kg/m2). A significant reduction in systolic and diastolic blood pressure, beginning after 1 month of treatment, was seen. There was no significant change in BMI. Although there was no obvious improvement in glucose metabolism, doxazosin treatment noticeably reduced insulin resistance and significantly lowered triglyceride and free fatty acid levels. No significant changes were found in total cholesterol, high- or low-density lipoprotein-cholesterol, atherosclerotic index, or small or large subfractions of low-density lipoprotein-cholesterol. None of the patients showed any adverse effects. The beneficial effects of doxazosin on blood pressure and lipid and glucose metabolism shown in this study suggest that this drug is clinically useful as an anti-hypertensive agent for patients with diabetes.
这项非对照研究调查了使用α1受体阻滞剂多沙唑嗪（每日2毫克或4毫克，持续3个月）治疗21例2型糖尿病高血压患者的效果，其中包括8名肥胖个体（体重指数[BMI]≥25.0千克/平方米）。治疗1个月后，收缩压和舒张压显著降低。BMI无显著变化。虽然糖代谢无明显改善，但多沙唑嗪治疗显著降低了胰岛素抵抗，并显著降低了甘油三酯和游离脂肪酸水平。总胆固醇、高密度或低密度脂蛋白胆固醇、动脉粥样硬化指数或低密度脂蛋白胆固醇的小或大亚组分均无显著变化。所有患者均未出现任何不良反应。本研究中多沙唑嗪对血压、脂质和糖代谢的有益作用表明，该药作为糖尿病患者的抗高血压药物在临床上是有用的。
